31.07.2013 • News • Dede Willams • DuPont • Q2 2013

DuPont Operating Profit Recedes by 16% in Q2

Sales of the DuPont group were virtually flat in Q2 2013, with the slight revenue setback of 1% to $9.8 billion blamed on poor pricing for the titanium dioxide business it plans to sell or spin off. Operating profit fell 16% year-on-year to $1.9 billion. Among business segments, Agriculture is credited with the best quarterly performance. For full year 2013, CEO Ellen Kullman said she expects DuPont to deliver earnings "modestly above 2012 results," thereby overcoming "steep declines" in the TiO2 market and economic headwinds in Europe.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.